Zhengye Biotechnology (ZYBT) Competitors $8.89 +1.14 (+14.71%) As of 05/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ZYBT vs. VERA, DYN, GPCR, ANIP, SPRY, CALT, ETNB, AMPH, OCUL, and BGMShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Amphastar Pharmaceuticals (AMPH), Ocular Therapeutix (OCUL), and Qilian International Holding Group (BGM). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Vera Therapeutics Dyne Therapeutics Structure Therapeutics ANI Pharmaceuticals ARS Pharmaceuticals Calliditas Therapeutics AB (publ) 89bio Amphastar Pharmaceuticals Ocular Therapeutix Qilian International Holding Group Zhengye Biotechnology (NASDAQ:ZYBT) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Which has better valuation & earnings, ZYBT or VERA? Zhengye Biotechnology has higher revenue and earnings than Vera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$189.75M2.21N/AN/AN/AVera TherapeuticsN/AN/A-$95.99M-$3.00-6.80 Do analysts rate ZYBT or VERA? Vera Therapeutics has a consensus price target of $63.33, indicating a potential upside of 210.61%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Does the MarketBeat Community believe in ZYBT or VERA? Vera Therapeutics received 43 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformZhengye BiotechnologyN/AN/AVera TherapeuticsOutperform Votes4366.15% Underperform Votes2233.85% Do institutionals & insiders believe in ZYBT or VERA? 99.2% of Vera Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ZYBT or VERA? In the previous week, Vera Therapeutics had 14 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 14 mentions for Vera Therapeutics and 0 mentions for Zhengye Biotechnology. Vera Therapeutics' average media sentiment score of 1.20 beat Zhengye Biotechnology's score of 0.67 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Zhengye Biotechnology Positive Vera Therapeutics Positive Is ZYBT or VERA more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Vera Therapeutics N/A -50.13%-39.50% SummaryVera Therapeutics beats Zhengye Biotechnology on 9 of the 12 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$365.54M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales2.21253.80392.34117.39Price / CashN/A65.8538.2534.62Price / BookN/A6.466.794.50Net IncomeN/A$143.98M$3.23B$248.18M7 Day Performance16.67%2.03%1.53%0.20%1 Month Performance-1.33%4.11%10.06%12.37%1 Year PerformanceN/A-2.87%16.72%7.04% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$8.89+14.7%N/AN/A$365.54M$189.75M0.00278Gap DownHigh Trading VolumeVERAVera Therapeutics3.3419 of 5 stars$21.58-4.0%$63.33+193.5%-48.7%$1.38BN/A-8.2740Positive NewsDYNDyne Therapeutics3.7388 of 5 stars$12.10-3.7%$46.85+287.2%-64.0%$1.37BN/A-3.40100Positive NewsGap DownGPCRStructure Therapeutics2.1114 of 5 stars$23.89-3.0%$78.00+226.5%-32.6%$1.37BN/A-32.28136ANIPANI Pharmaceuticals4.8258 of 5 stars$62.00-0.5%$80.13+29.2%-4.3%$1.35B$614.38M-112.73600SPRYARS Pharmaceuticals2.4068 of 5 stars$13.35+0.5%$31.00+132.2%+61.0%$1.31B$89.15M-26.1890Trending NewsAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180ETNB89bio2.7432 of 5 stars$7.80-3.8%$27.25+249.4%+7.4%$1.14BN/A-2.6840Positive NewsAMPHAmphastar Pharmaceuticals4.2439 of 5 stars$23.88-1.9%$32.33+35.4%-42.4%$1.13B$730.66M7.961,620OCULOcular Therapeutix4.2252 of 5 stars$7.00-5.3%$16.25+132.1%+19.7%$1.12B$59.65M-5.30230Gap UpBGMQilian International Holding GroupN/A$11.38+3.2%N/AN/A$1.11B$25.10M0.00298Positive NewsGap Up Related Companies and Tools Related Companies VERA Alternatives DYN Alternatives GPCR Alternatives ANIP Alternatives SPRY Alternatives CALT Alternatives ETNB Alternatives AMPH Alternatives OCUL Alternatives BGM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
